<p>蒙特利尔，魁北克 --（Newsfile Corp. -2026 年 3 月 2 日）- Defence Therapeutics Inc.（CSE: DTC）（FSE: DTC）（OTCQB: DTCFF）（“Defence” 或 “公司”），是一家公开交易的生物技术公司，利用其专有的 Accum®平台推进下一代治疗方案，今天概述了其参与 2026 年 3 月举行的一系列重大国际行业活动的计划。</p>
<p>这些高端会议将为 Defence 提供多个机会，以推进战略合作伙伴关系，加强其全球网络，并进一步将 Accum®定位为抗体药物偶联物（ADCs）、放射药物偶联物（RDCs）和其他复杂生物制剂的差异化细胞内递送技术。</p>
<p><strong>BIO-Europe Spring：主要关注战略合作伙伴关系</strong></p>
<p>Defence 将参加 BIO-Europe Spring（3 月 23-26 日，葡萄牙里斯本），这是生命科学行业的全球顶级合作活动。在 BIO-Europe 上，公司将优先与寻求合作以增强其 ADC 项目的细胞内递送和疗效的生物制药合作伙伴进行讨论，利用 Accum®。</p>
<p><strong>DCAT 周：推进生物制造能力</strong></p>
<p>Defence 还将参加 DCAT 周（3 月 23-26 日，纽约），公司将专注于加强其制造战略。在 DCAT 期间，Defence 计划与合同研究和制造合作伙伴会面，以推进 Accum®的强大和高质量的生物制造，这是公司的一个关键运营目标。Defence 最近已成为药物、化学及相关技术协会（“DCAT”）的成员，进一步加强了其确保 Accum®的良好特征、质量控制和商业化生产的承诺。</p>
<p><strong>扩大美国市场和投资者参与</strong></p>
<p>与此同时，Defence 将参加南佛罗里达生命科学展示会（3 月 24 日，迈阿密）和 FII PRIORITY 迈阿密（3 月 25-27 日），支持公司在美国的投资者外展和业务发展工作。Defence 最近还加入了 BioFlorida，进一步加强了其在佛罗里达生命科学生态系统中的影响力。</p>
<p>“在这些关键活动中与合作伙伴和行业利益相关者互动时，我们的首要任务是建立有意义的合作关系，以支持 Accum®的持续增长和采用，” Defence Therapeutics 的首席执行官 Sébastien Plouffe 表示。“通过实现更高效的复杂生物制剂细胞内递送，Accum®有潜力显著增强治疗效果和耐受性，使该平台在 ADC 领域成为颠覆性解决方案。” 如需探索合作机会或安排会议，请联系 Defence Therapeutics，邮箱为 info@defencetherapeutics.com。</p>
<p><strong>关于 Defence Therapeutics：</strong></p>
<p>Defence Therapeutics 是一家公开交易的生物技术公司，致力于使癌症治疗更有效和安全。利用其 Accum®精准药物递送平台，Defence 正在努力增强 ADCs 和其他复杂生物制剂的效力，以较低剂量实现减少副作用和改善先进疗法的可及性。通过追求前沿科学，并与制药和生物技术合作伙伴合作，Defence 力求为最需要的患者带来变革性疗法。要了解更多关于 Defence Therapeutics 的信息并探索合作机会，请访问 www.defencetherapeutics.com 或联系 info@defencetherapeutics.com。</p>
<p>如需进一步信息：</p>
<p>Defence Therapeutics</p>
<p>Sebastien Plouffe</p>
<p>首席执行官、创始人及董事</p>
<p>电话：（514）947-2272</p>
<p>Splouffe@defencetherapeutics.com</p>
<p>www.defencetherapeutics.com</p>
<p><strong>关于 “前瞻性” 信息的警示声明</strong></p>
<p>本发布包含某些可能被视为 “前瞻性声明” 的内容。除历史事实外，本发布中的所有声明，涉及公司预期发生的事件或发展，均为前瞻性声明。前瞻性声明是指不是历史事实的声明，通常但不总是通过 “预期”、“计划”、“预计”、“相信”、“打算”、“估计”、“项目”、“潜在” 等词语或 “将”、“会”、“可能”、“可以” 或 “应该” 发生的事件或条件来识别。尽管公司相信这些前瞻性声明中表达的期望是基于合理假设，但这些声明并不能保证未来的表现，实际结果可能与前瞻性声明中的内容有实质性差异。可能导致实际结果与前瞻性声明中的内容有实质性差异的因素包括监管行动、市场价格、资本和融资的持续可用性，以及一般经济、市场或商业条件。投资者被警告，任何此类声明都不是未来表现的保证，实际结果或发展可能与前瞻性声明中预测的内容有实质性差异。前瞻性声明基于公司管理层在声明发布时的信念、估计和意见。除非适用证券法要求，否则公司不承担在管理层的信念、估计或意见或其他因素发生变化时更新这些前瞻性声明的义务。</p>
<p>CSE 及其市场监管机构（根据 CSE 政策中的定义）对本发布的充分性或准确性不承担责任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/285690_a3c92e1684e79a2b_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/285690_a3c92e1684e79a2b_logo.jpg"/></p>
<p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/285690</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/285690/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/285690/375"/></p>

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做空纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

基因改革 ETF - ARK

<p>Defence Therapeutics Inc. 将在 2026 年 3 月的主要国际活动中展示其 Accum® 平台，包括 BIO-Europe Spring 和 DCAT Week，重点关注战略合作伙伴关系和生物制造能力。该公司旨在增强抗体药物偶联物和其他生物制剂的细胞内递送。此外，Defence 还将在南佛罗里达生命科学展示会和 FII PRIORITY Miami 与投资者进行交流，进一步巩固其在美国市场的存在。首席执行官 Sébastien Plouffe 强调了建立合作关系以支持 Accum® 在治疗领域增长的重要性</p>

<p>Montreal, Quebec--(Newsfile Corp. - March 2, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (&#34;Defence&#34; or the &#34;Company&#34;), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March 2026.</p>
<div class="lb-trans"><p>蒙特利尔，魁北克 --（Newsfile Corp. -2026 年 3 月 2 日）- Defence Therapeutics Inc.（CSE: DTC）（FSE: DTC）（OTCQB: DTCFF）（“Defence” 或 “公司”），是一家公开交易的生物技术公司，利用其专有的 Accum®平台推进下一代治疗方案，今天概述了其参与 2026 年 3 月举行的一系列重大国际行业活动的计划。</p>
</div><p>These high-profile meetings will provide Defence with multiple opportunities to advance strategic partnerships, strengthen its global network, and further position Accum® as a differentiated intracellular delivery technology for antibody-drug conjugates (ADCs), radiopharmaceutical conjugates (RDCs), and other complex biologics.</p>
<div class="lb-trans"><p>这些高端会议将为 Defence 提供多个机会，以推进战略合作伙伴关系，加强其全球网络，并进一步将 Accum®定位为抗体药物偶联物（ADCs）、放射药物偶联物（RDCs）和其他复杂生物制剂的差异化细胞内递送技术。</p>
</div><p><strong>BIO-Europe Spring: Primary Focus on Strategic Partnerships</strong></p>
<div class="lb-trans"><p><strong>BIO-Europe Spring：主要关注战略合作伙伴关系</strong></p>
</div><p>Defence will participate in BIO-Europe Spring (March 23-26, Lisbon, Portugal), the premier global partnering event for the life sciences industry. At BIO-Europe, the Company will prioritize discussions with biopharmaceutical partners seeking to collaborate on enhancing the intracellular delivery and efficacy of their ADC programs using Accum®.</p>
<div class="lb-trans"><p>Defence 将参加 BIO-Europe Spring（3 月 23-26 日，葡萄牙里斯本），这是生命科学行业的全球顶级合作活动。在 BIO-Europe 上，公司将优先与寻求合作以增强其 ADC 项目的细胞内递送和疗效的生物制药合作伙伴进行讨论，利用 Accum®。</p>
</div><p><strong>DCAT Week: Advancing Biomanufacturing Capabilities</strong></p>
<div class="lb-trans"><p><strong>DCAT 周：推进生物制造能力</strong></p>
</div><p>Defence will also attend DCAT Week (March 23-26, New York), where the Company will focus on strengthening its manufacturing strategy. During DCAT, Defence plans to meet with contract research and manufacturing partners to advance the robust and high-quality biomanufacturing of Accum®, a key operational objective for the Company. Defence has recently become a member of the Drug, Chemical &amp; Associated Technologies Association (&#34;DCAT&#34;), reinforcing its commitment to ensuring the well-characterized, quality-controlled, and commercially ready production of Accum®.</p>
<div class="lb-trans"><p>Defence 还将参加 DCAT 周（3 月 23-26 日，纽约），公司将专注于加强其制造战略。在 DCAT 期间，Defence 计划与合同研究和制造合作伙伴会面，以推进 Accum®的强大和高质量的生物制造，这是公司的一个关键运营目标。Defence 最近已成为药物、化学及相关技术协会（“DCAT”）的成员，进一步加强了其确保 Accum®的良好特征、质量控制和商业化生产的承诺。</p>
</div><p><strong>Expanding U.S. Presence and Investor Engagement</strong></p>
<div class="lb-trans"><p><strong>扩大美国市场和投资者参与</strong></p>
</div><p>In parallel, Defence will participate in the South Florida Life Sciences Showcase (March 24, Miami) and FII PRIORITY Miami (March 25-27), supporting the Company's ongoing investor outreach and business development efforts in the United States. Defence has also recently joined BioFlorida, further strengthening its footprint within the Florida life sciences ecosystem.</p>
<div class="lb-trans"><p>与此同时，Defence 将参加南佛罗里达生命科学展示会（3 月 24 日，迈阿密）和 FII PRIORITY 迈阿密（3 月 25-27 日），支持公司在美国的投资者外展和业务发展工作。Defence 最近还加入了 BioFlorida，进一步加强了其在佛罗里达生命科学生态系统中的影响力。</p>
</div><p>&#34;As we engage with partners and industry stakeholders across these key events, our priority is to build meaningful collaborations that support the continued growth and adoption of Accum®,&#34; said Sébastien Plouffe, CEO of Defence Therapeutics. &#34;By enabling more efficient intracellular delivery of complex biologics, Accum® has the potential to significantly enhance therapeutic performance and tolerability, positioning the platform as a game-changing solution in the ADC field.&#34;. To explore partnering opportunities or schedule a meeting, please contact Defence Therapeutics at info@defencetherapeutics.com.</p>
<div class="lb-trans"><p>“在这些关键活动中与合作伙伴和行业利益相关者互动时，我们的首要任务是建立有意义的合作关系，以支持 Accum®的持续增长和采用，” Defence Therapeutics 的首席执行官 Sébastien Plouffe 表示。“通过实现更高效的复杂生物制剂细胞内递送，Accum®有潜力显著增强治疗效果和耐受性，使该平台在 ADC 领域成为颠覆性解决方案。” 如需探索合作机会或安排会议，请联系 Defence Therapeutics，邮箱为 info@defencetherapeutics.com。</p>
</div><p><strong>About Defence Therapeutics:</strong></p>
<div class="lb-trans"><p><strong>关于 Defence Therapeutics：</strong></p>
</div><p>Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most. To learn more about Defence Therapeutics and explore partnering opportunities, please visit www.defencetherapeutics.com or contact info@defencetherapeutics.com.</p>
<div class="lb-trans"><p>Defence Therapeutics 是一家公开交易的生物技术公司，致力于使癌症治疗更有效和安全。利用其 Accum®精准药物递送平台，Defence 正在努力增强 ADCs 和其他复杂生物制剂的效力，以较低剂量实现减少副作用和改善先进疗法的可及性。通过追求前沿科学，并与制药和生物技术合作伙伴合作，Defence 力求为最需要的患者带来变革性疗法。要了解更多关于 Defence Therapeutics 的信息并探索合作机会，请访问 www.defencetherapeutics.com 或联系 info@defencetherapeutics.com。</p>
</div><p>For further information:</p>
<div class="lb-trans"><p>如需进一步信息：</p>
</div><p>Defence Therapeutics</p>
<div class="lb-trans"><p>Defence Therapeutics</p>
</div><p>Sebastien Plouffe</p>
<div class="lb-trans"><p>Sebastien Plouffe</p>
</div><p>CEO, Founder and Director</p>
<div class="lb-trans"><p>首席执行官、创始人及董事</p>
</div><p>P: (514) 947-2272</p>
<div class="lb-trans"><p>电话：（514）947-2272</p>
</div><p>Splouffe@defencetherapeutics.com</p>
<div class="lb-trans"><p>Splouffe@defencetherapeutics.com</p>
</div><p>www.defencetherapeutics.com</p>
<div class="lb-trans"><p>www.defencetherapeutics.com</p>
</div><p><strong>Cautionary Statement Regarding &#34;Forward-Looking&#34; Information</strong></p>
<div class="lb-trans"><p><strong>关于 “前瞻性” 信息的警示声明</strong></p>
</div><p>This release includes certain statements that may be deemed &#34;forward-looking statements&#34;. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words &#34;expects&#34;, &#34;plans&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;estimates&#34;, &#34;projects&#34;, &#34;potential&#34; and similar expressions, or that events or conditions &#34;will&#34;, &#34;would&#34;, &#34;may&#34;, &#34;could&#34; or &#34;should&#34; occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.</p>
<div class="lb-trans"><p>本发布包含某些可能被视为 “前瞻性声明” 的内容。除历史事实外，本发布中的所有声明，涉及公司预期发生的事件或发展，均为前瞻性声明。前瞻性声明是指不是历史事实的声明，通常但不总是通过 “预期”、“计划”、“预计”、“相信”、“打算”、“估计”、“项目”、“潜在” 等词语或 “将”、“会”、“可能”、“可以” 或 “应该” 发生的事件或条件来识别。尽管公司相信这些前瞻性声明中表达的期望是基于合理假设，但这些声明并不能保证未来的表现，实际结果可能与前瞻性声明中的内容有实质性差异。可能导致实际结果与前瞻性声明中的内容有实质性差异的因素包括监管行动、市场价格、资本和融资的持续可用性，以及一般经济、市场或商业条件。投资者被警告，任何此类声明都不是未来表现的保证，实际结果或发展可能与前瞻性声明中预测的内容有实质性差异。前瞻性声明基于公司管理层在声明发布时的信念、估计和意见。除非适用证券法要求，否则公司不承担在管理层的信念、估计或意见或其他因素发生变化时更新这些前瞻性声明的义务。</p>
</div><p>Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.</p>
<div class="lb-trans"><p>CSE 及其市场监管机构（根据 CSE 政策中的定义）对本发布的充分性或准确性不承担责任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8000/285690_a3c92e1684e79a2b_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/8000/285690_a3c92e1684e79a2b_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285690</p>
<div class="lb-trans"><p>要查看本新闻稿的源版本，请访问 https://www.newsfilecorp.com/release/285690</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/285690/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/285690/375"/></p>

Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March | DTCFF Stock News

StockTitan

Defence Therapeutics 将在三月份的重要国际行业活动中展示其 Accum 平台 | DTCFF 股票新闻